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ABSTRACT
OLANZAPINE-INDUCED LIVER INJURY: DIRECT METABOLIC EFFECTS,
EXACERBATION BY HIGH-FAT DIET, AND PROTECTION WITH
SULFORAPHANE

Robin H. Schmidt
07/08/2013

Olanzapine (OLZ) is an effective first-line treatment for schizophrenia and
bipolar disorder. The benefits of OLZ are countermanded by side effects such as
weight gain, glucose intolerance, dyslipidemia, and liver injury. These effects
impact not only antipsychotic medication compliance, but also increase the
health risks to patients. Most studies to date have focused on potential effects of
OLZ on the central nervous system (e.g., hypothalamic regulation of satiety);
however, peripheral changes in key metabolic organs such as the liver may also
play a critical role. The obesity rates in the US are now at epidemic levels and
obesity-induced liver disease (i.e., non-alcoholic fatty liver disease, or NAFLD) is
on the rise. It is now understood that obesity is a significant risk factor for a
myriad of drug-induced liver injuries. Given that the obesity incidence in the
psychiatric population is even higher than in the US population as a whole, the
effects of OLZ may exacerbate an underlying condition in these patients.

v

The purpose of this work was to determine the mechanisms of OLZinduced hepatic dysmetabolism, and to test the hypothesis that OLZ enhances
obesity-induced hepatic injury. OLZ was administered in a mouse model for four
weeks along with a high-fat diet (HFD) or low-fat control diet. OLZ alone
increased body weight and caused mild glucose intolerance, without a
commensurate increase in food consumption. OLZ alone also caused hepatic
steatosis and injury. Interestingly, although OLZ increased hepatic triglyceride
synthesis and storage, it did not increase the synthesis or abundance of hepatic
free fatty acids. OLZ administration appeared to cause a pseudo-fasted state
and dramatically depleted hepatic glycogen reserves. These effects of OLZ
occurred in parallel to significant changes in hepatic metabolite profiles. The
protein kinases AMPK and mTOR are generally differentially activated, and
mediate opposing metabolic functions; however, OLZ administration
simultaneously activated both AMPK and mTOR. When OLZ and HFD were
combined, there was an even greater increase in weight gain and glucose
intolerance. Liver damage from concurrent HFD and OLZ was worse than liver
damage resulting from HFD or OLZ alone.
Lastly, sulforaphane (SFN) was tested as a possible preventive against
HFD- and OLZ-induced toxicity. Some mice receiving HFD and OLZ were also
treated with SFN (90 mg/kg/d). SFN, a known inducer of the Nrf2 intrinsic
antioxidant pathway, prevented weight gain and liver injury and rescued hepatic
glycogen storage. Furthermore, SFN decreased the presence of 4hydroxynonenal (4HNE) adducts in liver (>20-fold), indicating that SFN treatment
vi

substantially limits oxidative stress in this model.
In summary, these data show that OLZ dysregulates glucose and lipid
metabolism and exacerbates hepatic changes caused by HFD exposure. The
outcomes of OLZ administration on hepatic metabolism may reflect, in part, the
contradictory inputs of simultaneous AMPK and mTOR activation. These data
indicate that the metabolic changes caused by OLZ may sensitize the liver to
injury caused by HFD and that underlying obesity/liver disease may aggravate
OLZ-induced side effects. The activation of intrinsic antioxidant defenses with
SFN can partially prevent these effects of OLZ and may represent a useful
strategy to protect against liver injury.
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CHAPTER I
INTRODUCTION

A.

Background and rationale for this study
1. Atypical antipsychotics: usage and side effects
Olanzapine (OLZ) is one of the most effective drug options for managing

the symptoms of schizophrenia and bipolar disorder.1,2 Much like earlier
antipsychotic drugs (e.g., haloperidol), OLZ and other second generation
antipsychotic medications bind antagonistically at dopamine receptors.3 Unlike
the earlier antipsychotic medications, OLZ binds and antagonizes serotonin
receptors, particularly the 5-HT2C receptor, and has a lower affinity for the D2
subclass of dopamine receptors. OLZ’s different affinities for various
neurotransmitter receptors may explain why it is less likely to cause tardive
dyskinesia and movement-related side effects than the previous generation of
drugs.4 Even among second generation antipsychotic drugs, OLZ is preferred for
its ability to treat psychiatric symptoms,5,6 and in contrast to the chemicallyrelated clozapine, there is little or no risk of developing blood disorders.7 These
attributes make OLZ a drug of choice to treat severe mental illness. Indeed, the
lack of debilitating side effects has advanced the off-label use of the drug for
indications such as dementia and treatment-resistant anxiety disorders.8,9
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Although OLZ does not share the severe toxicity of its first-generation
predecessors, it does have side effects that limit its therapeutic potential.
Numerous studies show that OLZ causes substantial and reproducible weight
gain.10-12 Though exact figures vary, a meta-analysis conducted by Allison et al.
found a mean weight gain of 4.0 kg after 10 weeks of OLZ administration.13
Weight gain with OLZ does not usually reach a rapid plateau, but rather
continues gradually throughout the years of treatment.10 Prescribing information
for Zyprexa, the brand-name formulation of OLZ, reports that the percent of adult
patients with weight gain >15kg was 4.3% after 6 months of OLZ administration,
14.1% after 12 months, 17.9% after 24 months and 22.5% after 36 months.14,15
Side effects such as weight gain are additionally correlated with decreased
treatment compliance.16,17 Overall, approximately 58% of patients requiring
antipsychotic medication do not adhere to treatment plans,18 leading to relapse
and increasing the need for costly inpatient psychiatric hospital stays.19,20
2. Overweight, obesity, and liver injury
Obesity is a major cause of preventable illness worldwide.21 In the United
States obesity has reached epidemic proportions, with approximately 68.6% of
Americans meeting the criteria for overweight (body mass index ≥ 25) and 33.8%
meeting the criteria for obesity (BMI ≥ 30) according to the most recent National
Health and Nutrition Examination Survey (NHANES III).22 Importantly, there is an
upward trend in BMI in the United States: the prevalence of obesity has doubled
since NHANES data were initially compiled in the 1960s.23
Among the myriad health complications associated with obesity (e.g.,
2

cardiovascular disease) is non-alcoholic fatty liver disease (NAFLD), which has
become one of the leading causes of chronic liver disease worldwide.24 NAFLD
is pathologically similar to alcoholic liver disease (ALD), but is distinguished by its
development in the absence of significant alcohol consumption.25 Apart from
obesity the risk factors for primary NAFLD include type II diabetes mellitus and
dyslipidemia. Though its features are well-defined, NAFLD is not a single,
uniform illness. Instead, it encompasses a spectrum of liver disease states,
ranging from simple steatosis, to active inflammation (non-alcoholic
steatohepatitis, or NASH), to advanced fibrosis and cirrhosis,26 and ultimately
hepatocellular carcinoma.27 Not all those with NAFLD are severely overweight;
however, the majority of NAFLD patients do have metabolic risk factors such as
obesity, hyperlipidemia, and/or type 2 diabetes mellitus.28 According to NHANES
III data, an estimated 32.5 million people – 21.7% of the United States
noninstitutionalized population between the ages of 20 and 74 – had some
degree of hepatic steatosis. Of these individuals, 28.8 million, or 90%, were
considered by NHANES to have NAFLD.29
3. Olanzapine, obesity, and hepatic metabolism
The side effects of OLZ are particularly relevant at this time, with obesity
increasing at an alarming rate in the US and other industrialized countries.30
Moreover, even within an increasingly overweight general population, obesity
disproportionately affects individuals with severe mental illnesses.31,32 When a
cohort of randomly selected psychiatric outpatients was compared to a gender-,
race- and age-matched group from NHANES III, the prevalence of obesity in the
3

outpatient psychiatric population was nearly double that of the NHANES group.33
Weight gain is not the only major metabolic effect of antipsychotic administration:
OLZ has also been associated with liver injury,34 dyslipidemia,35 and insulin
resistance.11,36 These effects, as mentioned previously, increase overall patient
mortality37 and strongly negatively influence patient treatment compliance. It is
therefore necessary to develop strategies that prevent, minimize, or reverse the
adverse metabolic effects that occur during OLZ treatment, especially for a
population already at risk for obesity and its sequelae.
The purpose of the work described in the chapters that follow was to
explore the effects of OLZ on indices of carbohydrate and lipid metabolism.
Ultimately, the goal was to determine relevant mechanisms in the development,
progression and treatment of OLZ-induced liver injury. The following hypotheses
are central to this dissertation:
B.

Aims and proposals
1. Does olanzapine directly alter hepatic energy metabolism?
Hepatic metabolism is paramount to this study for several reasons. First,

the liver is indispensable to whole-body glycemic control and lipid regulation.
The liver acts as a site for glucose uptake and gluconeogenesis, and provides a
large store of glycogen for the maintenance of blood glucose during fasting.38
Despite its somewhat small size in proportion to the rest of the body, the liver
accounts for ~20% of the body’s resting energy expenditure.39 Secondly,
regardless of whether it is administered orally or parenterally, OLZ reaches high
concentrations in liver, far surpassing levels in kidney, plasma and brain.40
4

Finally, the liver’s role in the development of metabolic side effects may be more
important than previously thought. The beneficial effects of OLZ are assumed to
be mediated at the level of the CNS. Not surprisingly, most studies into the
metabolic side effects of OLZ have also focused on the CNS. Although the CNS
clearly plays a key role in regulating food consumption, obesity, dyslipidemia and
diabetes,41-43 recent studies have suggested that the hepatic effects of OLZ
contribute to the drug’s metabolic disturbances.44 Interestingly, the changes
induced by OLZ administration in carbohydrate and lipid metabolism may in fact
precede weight gain, which suggests a potential direct effect of the drug on these
pathways.36,45 The purpose of the experiments described in Chapter III was to
determine what direct effects OLZ administration has on the liver, in the absence
of underlying illness or additional treatment.
2. Can OLZ act as a second “hit” in fatty liver diseases?
As described in the previous section, NAFLD is a spectrum of liver
diseases spanning from the relatively benign (steatosis) to the most severe (liver
cancer).27 The prevalence of simple steatosis in individuals at risk for NAFLD
can be very high; for example, the prevalence in individuals with a body mass
index (BMI) of 35 or greater has been reported to be 90%.46 In contrast, the
prevalence of NASH is much lower in this population (~40%).46 These factors
emphasize that the risk for developing more severe stages of NAFLD (i.e., NASH
and beyond) is not based solely on obesity, but is rather mitigated by genetic or
environmental factors – that is, disease progression is governed by the ‘2-hit’
paradigm. The paradigm proposes that physiological and/or biochemical
5

changes to liver that are pathologically inert can aggravate the hepatotoxic
response caused by a second agent.47,48 It is possible that OLZ treatment could
be such a previously unidentified agent in the progression of NAFLD. The
purpose of the experiments described in Chapter IV was to assess the impact of
OLZ on liver pathology in mice already predisposed to obesity and liver injury.
3. Can Nrf2 activation with sulforaphane protect against OLZ-induced
liver injury?
The formation of electrophilic and oxidative molecules is an invariable
consequence of normal metabolism.49 Reactive metabolites are generally
neutralized and excreted, though they may also serve as intermediates in cell
signaling.50,51 The oxidant-antioxidant equilibrium is, in most cases, wellregulated by a series of enzymes specifically evolved for this purpose. However,
an excess of oxidant species and/or a lack of antioxidant species will sometimes
develop, and it is this state of imbalance that is known as oxidative stress.52
Oxidative stress is not defined as a disease, though it is widely
hypothesized to be a common mechanism in the initiation or progression of many
diseases. Manifestations of oxidative stress such as lipid peroxidation are
repeatedly observed in conjunction with metabolic diseases.53-56 High levels of
fatty acids, cholesterol, and glucose produce reactive oxygen species,57-59 and
may therefore be crucial to the progression from obesity to more serious
illnesses such as NASH.60,61 It may also follow that the metabolic side effects of
OLZ can be prevented by antioxidants. Though the exact involvement of
antioxidant pathways in antipsychotic action is a matter of debate, OLZ was
6

recently reported to raise levels of malondialdehyde, a common biomarker for
oxidative stress.62
Past research has largely used direct antioxidants (e.g., vitamin C) to
prevent drug-induced oxidative stress. This approach has been more
consistently successful in vitro than in whole organisms. At worst, direct-acting
treatments actually induce disturbances in cellular redox status.63-65 A metaanalysis of clinical trials using vitamin E found that in high doses, vitamin E
significantly increases all-cause mortality.66 The toxicity of supplements such as
vitamin E may result from their dual nature: at high doses, many antioxidants act
as pro-oxidants.67,68 In contrast, indirect agents such as sulforaphane (SFN)
have neither reducing nor oxidizing capability.69,70 SFN instead works by
inducing Nrf2, thereby enhancing the cell’s own reducing capability and
supporting the function of endogenous detoxifying enzymes.71
There is already some evidence that alleviating oxidative stress can
alleviate the side effects of OLZ. Although high-dose vitamin E did not improve
insulin resistance in OLZ-medicated adults in a small clinical trial conducted by
Salmasi et al.,72 Shertzer et al. protected mice against OLZ-mediated metabolic
toxicity with tetrahydroindenoindole, an antioxidant,73 and acetaminophen, which
functioned as an antioxidant at the dose in which it was given.74 Similarly, a
study by Mas et al. used SFN to prevent oxidative stress in neuroblastoma cells
exposed to the second-generation antipsychotic drug risperidone.75 It remains
possible that oxidative stress is crucial to metabolic side effect development, but
there are few studies similar to those of Shertzer or Mas. The purpose of the
7

experiments described in Chapter V was to test Nrf2 induction (via SFN) as a
strategy against obesity- and OLZ-induced dysregulation of metabolism,
particularly in the liver.
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CHAPTER II
EXPERIMENTAL PROCEDURES

A. Animals and treatments
Female C57BL/6J mice (8 weeks old) were purchased from The Jackson
Laboratory (Bar Harbor, ME). Mice were housed in a pathogen-free barrier
facility accredited by the Association for Assessment and Accreditation of
Laboratory Animal Care. All procedures were approved by the University of
Louisville Institutional Animal Care and Use Committee.
Food and tap water were allowed ad libitum throughout the experiment,
except for a single 6 hour fast before glucose tolerance testing (see sections
below for more details). One week prior to the initiation of OLZ, animals were
switched from laboratory chow to standardized diets (Harlan Laboratories,
Madison, WI) to avoid any batch-to-batch variability in the food content.76 In
studies designed to test the effects of OLZ alone, pellets of TD.08485 (Low-Fat
Control Diet; 13% calories from fat) were supplied fresh twice per week. In
studies designed to test the interaction between OLZ and high-fat diet, pellets of
either TD.08485 or TD.88137 (Adjusted Calories Diet; 42% calories from fat)
were supplied fresh twice per week. Food consumption was estimated by

9

subtracting the weight of the pellets remaining at the end of each semi-weekly
feeding period.
B.

Chronic model of olanzapine exposure

Olanzapine (8 mg/kg/d) or vehicle (saline) was given s.c. for 28 days via
surgically implanted osmotic minipumps (Alzet, Cupertino, CA). This dose of
OLZ was previously determined by positron emission tomography scan to
achieve a therapeutically-relevant level of dopamine (D2) receptor occupancy in
mice.77 The s.c. route of administration was chosen to maintain a steady dosage
of OLZ, and because parenteral and oral formulations of OLZ have already
demonstrated comparable efficacy in vivo.78 To avoid concerns of OLZ
degradation, pumps were replaced after two weeks.79 Individual mouse weights
were recorded on a weekly basis. After 28 days, the mice were anesthetized
with ketamine/xylazine (100/15 mg/kg i.p.) and minipumps were removed and
weighed. Body composition was assessed by dual-energy x-ray absorptiometry
(DEXA Scan)80 using a Lunar PIXImus densitometer (Lunar Corp., Madison, WI).
Blood was collected from the vena cava just prior to sacrifice by exsanguination,
and citrated plasma was stored at −80 °C for later analysis. Portions of liver
tissue were frozen immediately in liquid nitrogen, fixed in 10% neutral buffered
formalin, or frozen-fixed in cold embedding medium (Tissue-Tek OCT compound,
Sakura Finetek, Torrance, CA) for subsequent sectioning and mounting on
microscope slides. Blood, liver, and gonadal fat pads were collected for later
analysis.
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C.

Oral glucose tolerance test (OGTT)
Glucose tolerance was evaluated at day 25 of OLZ exposure using an

OGTT method optimized by Andrikopoulos et al.81 Mice were transferred to
cages that had been cleared of food and bedding and fasted for 6 hrs. Blood
was sampled from the tail vein immediately after fasting, and then 15, 30, 60, 90
and 120 min. after oral administration of 2mg/kg D-(+)-glucose (Sigma, St. Louis,
MO) solution. Glucose concentrations were measured using an Accu-Chek®
Aviva Plus glucometer and test strips (Roche Diagnostics Corp., Indianapolis,
IN).
D.

Biochemical analyses
Plasma levels of alanine aminotransferase (ALT), aspartate

aminotransferase (AST), total cholesterol, HDL, LDL, VLDL, triglycerides (TG),
and glucose were determined by the Piccolo® Lipid Panel Plus Reagent Disc,
used with the Piccolo xpress™ Chemistry Analyzer (Abaxis, Inc., Union City,
CA), according to the manufacturer’s instructions.
E.

Hepatic lipid measurement
Hepatic lipids (TG and NEFA – non-esterified fatty acids) were extracted

as described by Bligh and Dyer.82 Briefly, mouse livers were pulverized in a
mortar filled with liquid nitrogen. Lipids were extracted from the pulverized tissue
by separation in a 1:2 solution of methanol and chloroform, then dried under
compressed nitrogen gas and resuspended in 5% fat-free bovine serum albumin
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(Sigma, St Louis, MO). Results were normalized to wet weight of extracted
tissue.
F.

Histology
1. General morphology
Hematoxylin and eosin (H&E) staining was used to assess overall hepatic

structure. Paraffin-embedded sections of liver (5 μm) were deparaffinized and
rehydrated, stained with hematoxylin for 45 seconds, washed, and
counterstained with eosin for 3 minutes. Stained sections were then mounted
with Permount (Fisher Scientific, Fair Lawn, NJ) and glass coverslips.
2. Neutral lipids
For detection of neutral lipids in tissue, 10 µm sections of frozen-fixed liver
embedded in OCT Compound were cut and stained with Oil Red O (Sigma
Chemical Co., St. Louis, MO) for 10 min., washed, and counterstained with
hematoxylin for 45 seconds before mounting with Crystal Mount™ (Sigma, St.
Louis, MO). The extent of oil Red O staining was defined as the percent of the
field area within the default color range determined by image analysis software.83
3. Glycogen and glycoprotein storage
Carbohydrate storage was visualized with Periodic acid-Schiff (PAS)
reagent staining. Paraffin sections were oxidized in 0.5% periodic acid solution
for 5 min., washed, placed in Schiff reagent (Sigma) for 15 min., washed, and
counter-stained with hematoxylin for 90 sec. Similar to Oil Red O staining, the
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extent of PAS staining was defined as the percent of the microscope field area
within the default color range determined by image analysis software.83
4. Lipid peroxidation
Adducts of 4-hydroxynonenal, an α,β-unsaturated hydroxyalkenal
produced by lipid peroxidation, were detected with a modified version of
immunohistochemical techniques described by Arteel et al.83,84 Specifically,
tissue sections were stained using a rabbit polyclonal 4-HNE antibody (Alpha
Diagnostic, San Antonio, Texas) and a kit based on a routine biotin-streptavidinperoxidase staining technique (VECTASTAIN ABC kit, Vector Laboratories,
Burlingame, CA). Once the antibody-biotin-peroxidase complex was formed,
diaminobenzidine (ImmPACT™ DAB peroxidase substrate, Vector Laboratories)
was added as the peroxidase substrate. After the immunostaining procedure,
tissue sections were counterstained with hematoxylin and mounted. Staining
was quantitated as the percentage of brown labeling (i.e., DAB) of the field area
minus the area of the acellular spaces.
5. Neutrophil accumulation
For measurement of hepatic neutrophil infiltration, the naphthol AS-D
chloroacetate esterase (CAE) kit (Sigma, St. Louis, MO) was used according to
the manufacturer’s instructions. CAE-positive cells were quantitated by counting
(positive cells per 1000 hepatocytes) in randomly selected fields.85
6. Apoptosis
Apoptosis was assessed by fluorescent TdT-mediated dUTP nick-end
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labeling (TUNEL) employing a commercially available kit (ApopTag® Red In Situ
Apoptosis Detection Kit, CHEMICON International, Temecula, CA). Slides were
mounted with VECTASHIELD mounting medium containing DAPI (Vector
Laboratories) and glass coverslips. Apoptotic cells were counted in the same
manner as CAE-positive cells (see Neutrophil accumulation above).
A MetaMorph™ image analysis system (Universal Imaging Corporation,
Downingtown, PA) equipped with a Nikon microscope (Nikon, Melville, NY) was
used to capture and analyze the results of the staining procedures described
above. Positive staining was not detected when tissues were processed without
primary antibody, indicating that nonspecific binding of secondary antibody did
not occur under these conditions.
G.

RNA Isolation and Real-Time RT-PCR
Message levels of selected genes were detected by real-time reverse-

transcriptase PCR. Total RNA was extracted from tissue samples by a guanidium
thiocyanate-based method (Tel-Test, Austin, TX). RNA concentrations were
determined spectrophotometrically, and 1 μg total RNA was reverse transcribed
using an MMLV reverse transcriptase kit (Quanta Biosciences, Gaithersburg,
MD). The cDNA was added to a mixture containing premade primers and probes
(Applied Biosystems, Foster City, CA) and a ready-to-use reaction buffer (Quanta
Biosciences). Amplification reactions were performed using ABI StepOne Plus
Software (Applied Biosystems). The comparative CT method was used to
determine fold differences between samples. The comparative CT method
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determines the amount of target, normalized to an endogenous reference (βactin) and relative to a calibrator (2-∆∆Ct).
H.

Glycogen Determination
To determine hepatic glycogen content, mouse livers (50-100 mg) were

weighed and placed immediately in 30% KOH (500 μl), digested at 100°C for 20
min, then cooled to room temperature. To the cooled digest, 95% EtOH (625 μl)
was added and allowed to stand overnight at room temperature. The samples
were then centrifuged at 16000 × g (4°C) for 15 min. The resultant pellet was
resuspended in 1ml water. Hepatic glycogen content was then determined with
anthrone reagent as described by Seifter et al.86 and modified for a 96-well plate
by Leyva et al.87 Glycogen content was calculated from glucose stand curve
and reported at μg/g tissue.
I.

Immunoblots
Frozen liver samples were homogenized (Polytron Kinematica, Lucerne,

Switzerland) in RIPA buffer (20 mM Tris pH 7.4, 150mM NaCl, 1mM EDTA, 1
mM EGTA, 1 mM β-glycerophosphate, 1 mM Na3VO4, and 1% w/w Triton X100) containing protease, tyrosine phosphatase, and serine/threonine
phosphatase inhibitor cocktails (Sigma, St. Louis, MO). Lysates were agitated
with an ultrasonic probe and subsequently centrifuged for 5 min. at 16,000 × g.
Protein concentration of the supernatants was determined with the Bio-Rad DC
Protein Assay (Bio-Rad, Hercules, CA, USA); 100 μg of total protein were mixed
with 4× sample loading buffer (250 mM Tris pH 7.4, 10% SDS, 20% 2mercaptoethanol, 40% glycerol and 0.01% w/v bromophenol blue) and incubated
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at 95°C for 5 min. Samples were loaded onto SDS–polyacrylamide gels (BioRad Laboratories, Hercules, CA), followed by electrophoresis and Western
blotting onto PVDF membranes (Hybond P, Amersham Biosciences, Piscataway,
NJ, USA). Antibodies against p-AMPKα, AMPKα, p-Akt, Akt, p-mTOR, mTOR, pp70S6K, p-4EBP1 (Cell Signaling, Danvers, MA, USA) and p70S6K and 4EBP1
(Bethyl Laboratories, Montgomery, TX) were used at the dilutions recommended
by the suppliers. Horseradish peroxidase-coupled secondary antibodies and
chemiluminescence detection reagents were from Pierce (Rockford, IL, USA).
The signals were detected employing Classic Blue™ autoradiography film BX
(MIDSCI, St. Louis, MO). Densitometric quantitation was performed with UNSCAN IT analysis software (Silk Scientific, Orem, UT).
J.

In vitro measurement of oxygen consumption and proton production

rates (OCR and PPR)
Bioenergetic measurements were made using an XF96 Extracellular Flux
Analyzer (Seahorse Biosciences, Billerica, MA). HepG2 cells (American Type
Culture Collection, Manassas, VA) were plated at 10,000 cells per well and
grown for 24 hrs. in DMEM (Gibco, Carlsbad, CA) containing either glucose (25
mM) or galactose (10 mM) and 6 mM pyruvate. (Immortalized cells preferentially
use glycolysis to meet energy demands, even in the presence of adequate
oxygen.88 Anaerobic glycolysis of galactose yields no net ATP, however, forcing
cells to rely on oxidative phosphorylation for survival.) Cells were then treated
with graded concentrations of olanzapine from 0–25 μM. One hour prior to the
commencement of measurements the media was changed to unbuffered DMEM
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(Seahorse Biosciences) containing the same concentrations of sugars, pyruvate
or olanzapine. The XF96 Extracellular Flux analyzer measures OCR (oxygen
consumption rate) and PPR (proton production rate) by creating a small transient
chamber in specialized plates. Seeding density was optimized under the cell
culture conditions described to ensure linear oxygen consumption and adequate
re-equilibration during the re-equilibration phases. Coupled and uncoupled OCR
and PPR measurements were made by addition of oligomycin (1 μg/ml) and
FCCP (1 μM), respectively, through sequential injections from ports in the
Seahorse Flux Pak cartridges.
K.

GC×GC-TOF MS and Pathway Analysis
1. Metabolite sample preparation
A sample of liver tissue was weighed and homogenized for 2 min after

adding water at a ratio of 100 mg liver tissue/mL water. The homogenized
sample was then stored at –80 °C until use. A 100 µL aliquot of the homogenized
liver sample and 400 µL ice cold methanol were mixed and vortexed for 2 min,
then incubated for 10 min on ice followed by another 2 min vortex. The mixtures
were centrifuged at 4 °C for 10 min at 15000 rpm. 400 µL of the supernatant was
aspirated into a micro centrifuge tube and dried by SpeedVac overnight. The
extracted metabolites were then dissolved in 40 µL acetonitrile. After adding 40
µL N-(tert-butyldimethylsilyl)-N-methyltrifluoroacetamide (MTBSTFA) mixed with
1% tert-butyldimethylchlorosilane (TBDMSCI), the mixture was sonicated for 3
hours followed by overnight derivatization at room temperature. The samples
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were then transferred to GC vials for analysis. The derivatization was performed
just before GC×GC–TOF MS analysis.
2. GC×GC –TOF MS analysis
The LECO Pegasus 4D GC×GC –TOF MS instrument was equipped with
an Agilent 6890 gas chromatograph and a Gerstel MPS2 auto-sampler
(GERSTEL Inc., Linthicum, MD), featuring a LECO two-stage cryogenic
modulator and secondary oven. The primary column was a 60 m × 0.25 mm 1dc
× 0.25 μm 1df, DB-5ms GC capillary column (phenyl arylene polymer virtually
equivalent to a (5%-phenyl)-methylpolysiloxane). A second GC column of 1 m ×
0.25 mm 1dc × 0.25 μm 2df, DB17ms ((50%-phenyl)-methylpolysiloxane) was
placed inside the secondary GC oven after the thermal modulator. Both columns
were obtained from Agilent Technologies (Agilent Technologies J&W, Santa
Clara, CA). The helium carrier gas (99.999% purity) flow rate was set to 2.0
mL/min at a corrected constant flow via pressure ramps. The inlet temperature
was set at 280 °C. The primary column temperature was programmed with an
initial temperature of 60 °C for 0.5 min and then ramped at 5 °C/min to 270 °C
and kept for 15 min. The secondary column temperature program was set to an
initial temperature of 70 °C for 0.5 min and then also ramped at the same
temperature gradient employed in the first column to 280 °C accordingly. The
thermal modulator was set to +15 °C relative to the primary oven, and a
modulation time of PM = 2 s was used. The mass range was set as 29−800 m/z
with an acquisition rate of 200 mass spectra per second. The ion source
chamber was set at 230 °C with the transfer line temperature set to 280 °C, and
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the detector voltage was 1450 V with electron energy of 70 eV. The acceleration
voltage was turned on after a solvent delay of 674 s. The split ratio was set at
25:1.
3. GC×GC–TOF MS data analysis
The GC×GC–TOF MS data were processed using LECO’s instrument
control software ChromaTOF for peak picking and tentative metabolite
identification, followed by retention index matching, peak merging, peak list
alignment, normalization, and statistical significance test using MetPP software.89
For metabolite identification using ChromaTOF, each chromatographic peak was
tentatively assigned to a metabolite if its experimental mass spectrum and a
database spectrum have a spectral similarity score no less than 600. The
retention index matching in MetPP was performed using the iMatch method with
the p-value threshold set as p ≤ 0.001.90 The pairwise two-tail t-test was used to
determine whether a metabolite has a significance abundance difference
between sample groups by setting the threshold of false discovery rate q ≤ 0.3.
L.

Sulforaphane administration
Sulforaphane (SFN), a known Nrf2 inducer, was investigated as a possible

preventative measure against weight gain and oxidative injury. In the
experiments discussed in Chapter V, mice received SFN diluted in water (90
mg/kg/d p.o.; LKT Laboratories, St. Paul, MN) alongside chronic OLZ treatment
and HFD feeding. SFN treatment began one week prior to OLZ administration
(see Chapter II, section B, Chronic model of olanzapine exposure) and continued
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until the day of sacrifice. Mice not receiving sulforaphane received equivalent
volumes of water as a treatment control.
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CHAPTER III
NEW MECHANISTIC INSIGHT INTO OLANZAPINE-INDUCED METABOLIC
DYSFUNCTION

A.

Introduction
The atypical antipsychotic olanzapine is a first-line treatment for psychosis

and mood disorders. The major side effects of this centrally-acting drug occur in
the peripheral tissues: weight gain, hepatic steatosis, and glucose intolerance.
The exact mechanism or mechanisms leading to side effect development with
OLZ are unknown. The purpose of the following experiments was to reveal the
biochemical pathways involved in OLZ metabolism and toxicity, primarily in liver.
B.

Experimental procedures
1. Animals and treatments
All mice in this experiment were fed purified TD.08485 diet starting one

week prior to administration of OLZ or vehicle. OLZ administration and sacrifice
procedures are described in Chapter II. See also: Timeline, Figure 3.1, panel A.
2. Oral glucose tolerance test
Glucose tolerance testing was performed as described in Chapter II.
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3. Biochemical analyses and histology
ALT, AST, cholesterol, TG and glucose were determined in plasma after
four weeks of OLZ administration according to the methods detailed in Chapter II.
Liver sections were stained with H&E, Oil Red O, and Periodic acid-Schiff
reagent as described in Chapter II.
4. RNA isolation and real-time RT-PCR
See detailed methods in Chapter II.
5. Immunoblots
Immunoblotting was used to assess the phosphorylation status of mTOR,
AMPK, 4EBP1, p70S6K and Akt, as described in Chapter II.
6. In vitro metabolic measurements
HepG2 cells were exposed to varying concentrations of OLZ and
measured with an extracellular flux analyzer as described in Chapter II.
7. Metabolomic analyses
GC×GC-TOF MS was performed and the results were analyzed as
previously described in Chapter II.
C.

Results
1. OLZ administration increases weight and adiposity
All animals gained weight during the course of the study and there was no

mortality in any group. OLZ administration did not significantly increase food
consumption compared to animals administered vehicle (“control”). Although
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food consumption measurements for each group were nearly identical, OLZ
administration significantly increased body weight by ~40% over controls (Figure
3.2, panel A), similar to what has been observed previously by other groups.91
An increase in body fat percentage and gonadal fat pad mass accompanied the
weight gain (Figure 3.2, panel B) in OLZ-exposed animals.
2. OLZ promotes hepatic lipid accumulation
Obesity and/or metabolic syndrome commonly cause lipids to accumulate
in the liver (i.e., steatosis).61 As OLZ administration increased body weight and
total body fat (Figure 3.2), the effect of OLZ on hepatic lipid accumulation was
determined. A crude index of hepatic lipid accumulation is liver size. OLZ
increased liver weight as indicated by the elevation in liver weight to body weight
ratio (Figure 3.3, panel C). Four weeks of OLZ treatment also increased hepatic
fat, as indicated by the presence of macro- and micro-vesicular lipid droplets in
hematoxylin and eosin-stained tissue (Figure 3.3, panel A, top). This effect of
OLZ on hepatic lipid accumulation was confirmed by Oil Red O staining (panel A,
bottom). OLZ administration significantly elevated hepatic triglyceride (TG)
content ~2-fold (Figure 3.3, panel B); interestingly, this increase in TG was not
coupled with a concomitant increase in hepatic non-esterified fatty acids (NEFA).
This increase in hepatic lipids was paralleled by a significant increase in plasma
triglycerides and VLDL (Table 3.1). These effects of OLZ were also
accompanied by liver injury, as indicated by significant elevations of plasma ALT
(~2-fold) and AST (~1.5 fold; Table 3.1).
3. OLZ modifies expression of metabolism-regulating genes
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Hepatic steatosis is often mediated via direct alterations in the expression
of genes key to lipid and carbohydrate metabolism. To explore the effects of
OLZ on hepatic energy metabolism, mRNA expression of genes that are key in
regulating the synthesis and catabolism of carbohydrates and lipids was
examined by qRT-PCR (Figure 3.4). Four weeks of OLZ administration
significantly downregulated the expression of a number of genes involved in lipid
biosynthesis, including sterol regulatory element-binding protein 1 (Srebf1), fatty
acid synthase (Fasn), and ATP citrate lyase (Acly). Similarly, OLZ treatment
upregulated expression of glycogen synthase kinase-3β (Gsk3b), a protein that
suppresses glycogen synthesis. These changes in expression of anabolismregulating genes were accompanied by a significant (2.5-fold) increase in
expression of glucokinase (Gck), a rate-limiting enzyme in glycolysis. Expression
of carnitine palmitoyltransferase 1a (Cpt1a), which encodes the rate-limiting
enzyme in fatty acid β-oxidation, was unchanged, as were phosphoenolpyruvate
carboxykinase 1 (Pck1; gluconeogenesis) and glucose transporter type 1 and
glucose transporter type 4 (Glut1 and Glut4; basal and insulin-mediated glucose
transport, respectively).
4. Effects of OLZ on mitochondrial respiration
The mRNA expression data suggest that OLZ administration favors
glycolysis (Figure 3.4). Previous studies with isolated brain mitochondria have
suggested that OLZ partially inhibits mitochondrial respiration (e.g.,92). The effect
of OLZ exposure on the balance between glycolysis and mitochondrial
respiration was therefore determined in vitro in HepG2 cells by Seahorse in both
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glucose- and galactose-containing media (see Experimental Procedures in
Chapter II and diagram in Figure 3.5). Under these conditions, proton production
rate (PPR) is used as an index of glycolysis, and the oxygen consumption rate
(OCR) is used as an index of mitochondrial function (Figure. 3.7). As expected,
inhibition of mitochondrial respiration with oligomycin, which forced the cells to
rely on anaerobic glycolysis, decreased the rate of OCR, while simultaneously
increasing the rate of PPR, thereby greatly increasing the PPR:OCR ratio.
Uncoupling the mitochondria with FCCP increased the OCR while still
maintaining an elevated PPR, causing the PPR:OCR ratio to decrease relative to
oligomycin, but still remain elevated relative to basal (Figure 3.7, panels A, B, C,
D, E, and F). In glucose-containing media, OLZ had no apparent effect on OCR
or PPR at any concentration. When the Warburg/Crabtree effect was overcome
by incubating HepG2 cells in galactose-containing media,88 the ratio of PPR:OCR
was dramatically decreased, as the cells were forced to rely on oxidative
phosphorylation.93 Under these conditions, OLZ incubation caused a dosedependent increase in PPR, without significantly affecting OCR (panels G and
H).
5. Effects of OLZ on glucose and glycogen expenditure
OLZ increased basal (unfasted) plasma glucose, as indicated by plasma
taken at sacrifice (Table 3.1). Previous studies have indicated that OLZ
administration may cause insulin resistance and/or glucose intolerance.94 OLZ
also antagonizes serotonin, which is a positive mediator of glycogen synthesis.95
To determine if OLZ administration under the current conditions affected glucose
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tolerance, fasted mice were subjected to the OGTT at 25 days of vehicle or drug
administration (see Experimental Procedures in Chapter II and Figure 3.7, panel
A in this chapter). OLZ exposure significantly increased plasma glucose
concentrations 15 minutes after bolus gavage (panel A), but values were similar
to controls at all subsequent time points. As mentioned above, the expression of
a key inhibitor of glycogen storage (Gsk3b) was significantly increased in livers of
OLZ-exposed mice (see Figure 3.4). The effect of OLZ administration on hepatic
glycogen storage was therefore assessed by Periodic acid-Schiff reagent (PAS)
staining. OLZ administration decreased the amount of glycogen stored in
unfasted liver by 2-fold compared to controls (Figure 3.7, panel B, representative
photomicrographs, and panel C, quantitative image analysis).
6. OLZ effects on the hepatic metabolome
Examining metabolites on an individual basis is time-consuming, and the
smaller amounts of data produced may unnecessarily narrow the scope of a
study. Metabolomic analysis was therefore used to simultaneously characterize
several effects of OLZ on the liver (Figure 3.8). Metabolites that varied
significantly between the OLZ group and the control group were then analyzed
with pathway analysis software, which predicted and mapped the pathways that
may be relevant to OLZ treatment (Figure 3.9). Among other findings, levels of
amino acids were significantly affected by OLZ: L-glutamine, a putative mediator
of insulin secretion96 and mTOR activation,97 was increased in animals
administered OLZ. Network analysis further predicted the involvement of amino
acid transporters Slc7a5 (LAT1) and Slc38a2 (SNAT2), which were recently
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shown to function as regulators of mTOR signaling,97-99 and EAAT3, which
conversely is regulated by mTOR.100
7. OLZ mediates signaling through mTOR and related pathways
OLZ administration has been shown to increase peripheral levels of
glutamate,101,102 which can increase the flux of branched chain amino acids
(BCAAs) and/or branched chain α -ketoacids in tissue.103,104 BCAAs,105 their αketoacid analogs,106 and glutamine107 have all been identified as potential
activators of mammalian target of rapamycin (mTOR) and/or mTOR-dependent
signaling cascades. Atypical antipsychotics have also been shown to increase
glutamine in the brains of postmortem schizophrenia patients.108 Given the key
role of mTOR in bioenergetic regulation109 and the effects of OLZ on glutamine,
(Figure 3.8), mTOR and related proteins were examined by Western blot (Figure
3.10). OLZ administration increased mTOR activation, as indicated by a
significant increase in phosphorylation at Ser2448.110 OLZ administration also
increased phosphorylation of p70S6K at Thr389 and 4EBP1 at Thr37/46,
indicating mTORC1 activation,111 as well as Akt phosphorylation at Ser473,
indicating mTORC2 activation.112 Strangely, OLZ treatment concomitantly
increased AMPK activation (Figure 3.10), as indicated by an increase in
phosphorylation at Thr172.113
D.

Discussion
The serotonin-dopamine antagonist OLZ is a valuable addition to the

psychiatric pharmacopeia, but it also presents new challenges for doctors and
patients.114 Despite the lack of dyskinetic side effects that result from use of
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older antipsychotics, OLZ causes a number of adverse effects that restrict its
use, such as obesity and elevated cholesterol. In order for patients to benefit
from OLZ without suffering additional metabolic complications, preventive agents
and/or treatments must be aimed at the root causes of dysmetabolism during
OLZ treatment. Thus far the origins of OLZ dysmetabolism have been elusive,
as even the mechanisms that mediate OLZ’s desirable therapeutic effects are
poorly understood.
The findings from this study – namely, that OLZ activates both AMPK and
mTOR, and that this activation may result from altered amino acid transport (see
diagram, Figure 3.11) – are therefore important steps toward improving the
safety and tolerability of antipsychotic treatment. An earlier intervention
proposed for the metabolic side effects of OLZ was metformin, a biguanide drug
often prescribed for type II diabetes. Clinical trials of metformin as an adjunct to
OLZ therapy have shown disappointingly little improvement in metabolic
symptoms, however.115 This lack of effect may be due to the fact that AMPK
activation is a major mechanism of action for metformin, and AMPK is already
activated by OLZ administration.
Targeting mTOR may instead work better than targeting AMPK. It has
been suggested that “normalizing” mTOR overactivation could be beneficial for
managing obesity and diabetes.116 While OLZ-mediated dysmetabolism differs
slightly from most cases of metabolic syndrome – a point which is clearly
illustrated by the differential activation of AMPK – the effects on mTOR appear
similar in both situations. Unlike metformin, then, an mTOR-inhibiting drug such
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as tacrolimus, given at a sub-immunosuppressive dose, may be applicable in
both primary and OLZ-mediated metabolic dysfunction.
Future studies will be needed to confirm the therapeutic significance of
mTOR suppression as an adjunct to antipsychotic therapy. In certain
experimental models, mTOR inhibitors like rapamycin have exacerbated glucose
intolerance117 and dyslipidemia;118 in other studies, mTOR inhibitors have
improved metabolic homeostasis.119-121 Appropriate dosing appears crucial to
the ultimate outcome of treatment with mTOR inhibitors.122 It should also be
determined what effects, if any, mTOR inhibitors have on mental functioning and
overall OLZ efficacy. The glutamatergic model of mental illness proposes that
antipsychotic disorders are disorders of excitatory amino acid metabolism.123
Targeting mTOR, then, would be arguably “downstream” of OLZ’s psychiatric
effects.

29

Table 3.1: Plasma parameters after 4 weeks of OLZ treatment

Glucose

(mg/dL)

Control
196 ± 6

OLZ
329 ± 13*

TG

(mg/dL)

42 ± 2

80 ± 7*

Cholesterol

(mg/dL)

50 ± 6

62 ± 3

HDL

(mg/dL)

34 ± 4

42 ± 4

LDL

(mg/dL)

8±2

4±2

VLDL

(mg/dL)

9±1

16 ± 1*

ALT

(U/L)

33 ± 9

76 ± 9*

AST

(U/L)

56 ± 2

80 ± 6*

Animals and treatments are described in Experimental Procedures. Data
are means ±S.E.M. (n=4-8) and are reported as indicated in the individual rows.
*, P < .05 compared to no OLZ treatment.
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Figure 3.1: Experimental timeline

Mice were switched to purified TD.08485 diet one week prior to OLZ
administration (8 mg/kg/d, s.c.). Oral glucose tolerance testing (OGTT) was
performed after 25 days of OLZ administration. After four weeks of continuous
OLZ, mice were sacrificed as described in Chapter II.
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Figure 3.2: Effect of OLZ on body weight gain and adiposity

Mice were treated with OLZ for four weeks as described in Chapter II.
Average weekly food consumption and weight gain are shown (panel A). Body
fat as a percentage of total body weight was measured by x-ray absorptiometry
and gonadal fat pads were removed and weighed at sacrifice (panel B). Data are
means ±S.E.M.(n=4-8). *, P < .05 compared to no OLZ treatment.

33

A.

B.

food consumption (g/week)
weight gain (g/week)

fat pad weight:body weight %
body fat %

2

1

0

0

Control

*
*
20

1

10

0

0

Control

OLZ

34

OLZ

Body Fat

1

Fat Pad:Body Weight

*
Weight Gain

Food Consumption

30

2

3

Figure 3.3: OLZ promotes hepatic lipid accumulation

General histology is represented by hematoxylin and eosin staining (panel
A, top). Neutral lipid accumulation is shown with Oil Red O staining (panel A,
bottom). Hepatic triglyceride (TG) and non-esterified fatty acid (NEFA) contents
(panel B) were determined after chloroform:methanol extraction as described in
Experimental Procedures. Liver weight measurements taken at sacrifice are
expressed as a percentage of total body weight, also measured at sacrifice
(panel C). Data are means ±S.E.M.(n=4-8). *, P < .05 compared to no OLZ
treatment.

35

36

Figure 3.4: Effects of OLZ on hepatic gene expression

Hepatic mRNA expression of genes for lipid metabolism (top) and
carbohydrate metabolism (bottom) was determined by qRT-PCR after four weeks
of continuous OLZ treatment, as described in Experimental Procedures. Data
are means ±S.E.M.(n=4-8). *, P < .05 compared to no OLZ treatment.
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Figure 3.5: Glucose vs. galactose media for immortalized cells

Panel A: In primary cells (“normal” cells), energy requirements are mostly
met by producing ATP via oxidative phosphorylation (OXPHOS), with glycolysis
making a small contribution to overall energy status. Immortalized cells, in
contrast, primarily generate ATP through glycolysis. Panel B: Because
metabolism of galactose produces no net ATP, immortalized cells must rely on
OXPHOS to fulfill ATP needs.
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Figure 3.6: In vitro metabolism of OLZ-treated HepG2 cells
Respiration was measured in HepG2 cells grown in either glucose or
galactose and graded concentrations of OLZ (0 – 25 μM). PPR (panels A and
B), OCR (panels C and D), and PPR:OCR (panels E and F) are shown as a
function of time for 0 and 25 μM OLZ, with both glucose and galactose media.
Measurements of PPR and OCR are also shown for galactose-grown cells in
panels G and H Basal = 10 minutes before the addition of oligomycin; Oligo = 10
minutes after the addition of oligomycin. *, P < .05 compared to no OLZ
treatment.
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Figure 3.7: Effects of OLZ on glucose and glycogen expenditure

Glucose tolerance (panel A) was assessed as described in Experimental
Procedures. Liver sections were stained with Periodic acid-Schiff reagent and
representative photomicrographs are depicted (panel B). PAS staining was
quantitated (panel C) as described in Chapter II. Data are means ±S.E.M.(n=48). *, P < .05 compared to no OLZ treatment.
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Figure 3.8: OLZ effects on the hepatic metabolome

Liver samples were derivatized as described in Chapter II and metabolites
determined by GC×GC-TOF MS. Relative abundance data is shown for selected
small molecule metabolites. Data are means ±S.E.M.(n=4-8). *, P < .05
compared to no OLZ treatment.
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Figure 3.9: Metabolic pathways

Metabolites identified by GC×GC-TOF MS were evaluated with
MetaCore™ software and used to construct a pathway map. Targets related to
mTOR and amino acid metabolism are enlarged and shown beneath the map.
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Figure 3.10: OLZ mediates signaling through mTOR and related pathways

Liver homogenates were prepared as described in Experimental
Procedures, Chapter II. Representative immunoblots are shown (panel A).
Quantitative analysis was performed and the ratio of phosphorylated to total
protein is shown in (panel B). *, P < .05 compared to no OLZ treatment.
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Figure 3.11: Hypothesized mechanism of OLZ-induced metabolic
dysregulation in liver

OLZ promotes flux of glutamine (Gln) and leucine (Leu) through solute
carrier 38a2 (SLC38A2 or SNAT2) and solute carrier 7a5 (SLC7A5 or LAT1).
Increased concentrations of Gln and Leu induce mTOR signaling. Excess
intracellular Leu acts as a nitrogen donor in the branched chain aminotransferase
(BCAT) reaction that forms glutamate (Glu). Leu and Glu also contribute
metabolic intermediates (e.g., acetyl CoA) to the Krebs cycle. Interestingly,
AMPK was simultaneously activated under these conditions (see discussion in
Chapter VI for additional information).
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CHAPTER IV
HIGH-FAT DIET EXACERBATES OLANZAPINE-INDUCED LIVER INJURY

A.

Introduction
In the preceding sections of this dissertation it was noted that weight gain

and obesity caused by OLZ are serious health risks as well as barriers to
successful treatment of mental illness. OLZ administration causes weight gain in
normal-weight individuals; OLZ use may then be especially detrimental for
overweight patients or patients who consume high-fat, high-calorie diets. Indeed,
OLZ has been shown to “unmask” metabolic syndrome and type II diabetes in
previously asymptomatic individuals.32,124,125 The purpose of these experiments,
therefore, was to determine the interactions that result from concurrent OLZ
administration and HFD feeding, and to isolate the unique pathological features
of these interactions.
B.

Experimental Procedures
1. Animals and treatments
Mice were separated into four groups (2x2 factorial design), receiving

either TD.08485 low-fat or TD.88137 high-fat diet and either OLZ or vehicle
control. Diets were started one week before the four week drug administration
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period. Drug administration and sacrifice procedure are described in greater
detail in the Experimental Procedures chapter (Chapter II).
2. Oral glucose tolerance test (OGTT)
Glucose tolerance testing was performed as described in Chapter II.
3. Glycogen determinations
Glycogen was measured in liver tissue aliquots as described in Chapter II.
4. RNA isolation and real-time RT-PCR
Details for RNA isolation and PCR procedure are found in Chapter II.
5. Biochemical analyses and histology
Liver sections were stained with H&E, Oil Red O, CAE, PAS, TUNEL and
4- HNE as described in Chapter II.
6. Lipid determinations
Hepatic lipids were measured as previously discussed in Chapter II.
C.

Results
1. High-fat diet (HFD) increases food consumption and exacerbates

weight gain caused by OLZ
All animals gained weight over the course of the study and no mortality
was observed in any group. Mice fed HFD consumed more food and gained
more weight on average than mice fed LFD (Figure 4.2, panels A and B). OLZ
did not have any effect on food consumption, but added to body weight gain in
both diet groups. OLZ also increased the ratio of gonadal fat mass to total body
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mass, which was further increased by concurrent HFD feeding (panel C). OLZ
and HFD promoted overall body fat accumulation as shown by DEXA scan
(representative images, panel D).
2. HFD aggravates OLZ-induced liver injury
Previous studies have shown that feeding mice a diet enriched in
triglycerides and cholesterol (i.e., the “Western diet”) damages the liver and may
contribute to the onset of NAFLD. Studies from this laboratory have also linked
OLZ administration to early indices of liver damage. Liver injury was indeed
observed in OLZ-treated animals, and this liver injury was aggravated by
concurrent HFD feeding. As in previous work, four weeks of OLZ increased fat
accumulation across all regions of the liver, as shown by H&E staining (Figure
4.3, panel A, top row). Co-administration of HFD further increased the fat
accumulation resulting from OLZ alone. Neutrophil infiltration in liver was
increased by HFD or OLZ alone, and more so by HFD and OLZ together
(representative pictures in bottom row of panel A and cell counting, panel D).
OLZ administration elevated circulating hepatic transaminases, a common
indicator of hepatocyte death (panels B and C). HFD alone had no effect on
transaminase levels; however, in conjunction with OLZ, HFD raised ALT and
AST to levels greater than OLZ alone. OLZ and HFD separately increased the
liver weight to body weight ratio, but the combination of OLZ and HFD produced
no additional change (panel E).
3. OLZ and HFD promote hepatic lipid storage
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Hematoxylin and eosin staining had demonstrated steatosis with OLZ and
HFD both alone and in combination. Therefore, frozen liver sections were
stained with Oil Red O (Figure 4.4, panel A) and staining intensity (i.e., extent of
lipid accumulation) was quantitated (panel B). Minimal staining intensity was
seen with LFD feeding, indicating very little hepatic fat accumulation. OLZ
administration caused a 1.5-fold increase in micro- and macrovesicular steatosis,
as determined by image analysis. HFD by itself caused a 2-fold increase in
steatosis. When OLZ and HFD were administered together, steatosis increased
2.5-fold compared to LFD alone. Hepatic lipid extraction elaborated upon these
Oil Red O data: OLZ and HFD separately doubled triglyceride (TG) content in
liver, and together increased TG fourfold (panel C). Hepatic free fatty acids
(NEFA) were elevated with HFD alone, but remained stable in all other treatment
groups.
4. Effects of OLZ and HFD on glucose metabolism
In vivo glucose metabolism was measured by oral glucose tolerance test
(OGTT) after 25 days of drug administration and LFD or HFD consumption (see
Experimental Procedures for additional details). Four weeks of OLZ and/or HFD
did not significantly alter plasma glucose concentrations after a 6 hour fast
(Figure 4.5, panel A). Following bolus glucose administration, however, plasma
glucose was markedly elevated in both HFD- and OLZ-exposed animals.
Exposure to OLZ and/or HFD also influenced glucose kinetics. In mice given
OLZ and HFD, either separately or in combination, peak plasma glucose was
observed at 15 minutes in contrast to 30 minutes for LFD-fed controls.
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Interestingly, at the 30 minute time point, plasma glucose remained elevated in
mice given HFD alone, but rapidly declined in mice given HFD and OLZ together.
5. HFD worsens OLZ-induced glycogen depletion
A previous study by this group showed that OLZ exposure attenuated
glycogen storage in liver. Here, the interaction between OLZ and HFD was
investigated. Periodic acid-Schiff (PAS) staining showed that OLZ alone and
HFD alone decreased hepatic glycogen reserves (Figure 4.5, panels B and C).
Glycogen was additionally depleted by co-administration of OLZ and HFD.
6. Effects of HFD and OLZ on apoptosis and lipid peroxidation
To better determine the cause of aggravated liver injury with concurrent
HFD and OLZ, liver sections were stained for markers of apoptosis and lipid
peroxidation. Though few apoptotic cells were counted in any treatment group,
HFD alone doubled the number of TUNEL-positive cells per 1,000 hepatocytes
counted (Figure 4.6, panels A and B). No additional change was seen with HFD
and OLZ in combination. Lipid peroxidation increased ~6-fold with OLZ alone,
and ~8-fold with HFD and OLZ in combination (panel C).
D.

Discussion
According to the “two hit” hypothesis, now widely accepted in the field of

hepatology, liver disease development requires two or more compounding
factors. The first factor, or “hit,” increases sensitivity to injury by later insults. For
example, injecting mice with lipopolysaccharide (LPS) provokes an immune
response and produces mild liver injury. If the same mice are exposed to alcohol
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shortly afterward, liver injury becomes exponentially worse.126 The order of these
two hits is probably not as important as the fact they occur in succession. In an
experiment by Yang et al. using obese (fa/fa) Zucker rats, LPS functioned as a
second hit; the widespread hepatic steatosis already present in this genetic strain
is considered to represent the first hit.48
In the experiments reported in Chapter IV of this work, a different but
complementary two-hit phenomenon was observed. OLZ produced toxic effects
with both high- and low-fat diets, but the combined effects of OLZ and HFD
noticeably exacerbated toxicity, increasing fat accumulation and inflammatory
response, among other observable injuries. Oxidative stress also markedly
worsened during HFD + OLZ co-exposure. These results parallel both Yang’s
work and much subsequent research. The HFD + OLZ model, in demonstrating
multiplied injury, maintains rather than innovates an important toxicological
concept.
The importance of the HFD + OLZ model instead arises from its
implications for two overlapping clinical populations. As mentioned in Chapter I,
a majority of Americans today are overweight. Of this overweight population,
nearly half are obese (BMI ≥ 30). Rates of overweight and obesity have
increased over the last 50 years and show no evidence of decline. While the
prevalence of schizophrenia and affective disorders is much smaller (~14%),127,128 the large and expanding proportions of the national weight problem
increase the likelihood of a hepatotoxic two-hit interaction.

58

Taken together, the results from this study illustrate the concept that more
serious liver diseases may require multiple factors in their progression. This
demonstrates the need for additional monitoring of overweight or obese patients
who also take olanzapine. Also, because oxidative stress and inflammation were
shown to worsen with HFD and OLZ, potential pharmacological interventions
should be aimed at suppressing oxidative injury and/or exaggerated inflammatory
response.
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Figure 4.1: Experimental timeline

Mice were switched to purified low- or high-fat diets (LFD or HFD) one
week prior to OLZ administration (8 mg/kg/d, s.c.). Oral glucose tolerance testing
(OGTT) was performed after 25 days of OLZ administration. After four weeks of
continuous OLZ, mice were sacrificed as described in Chapter II.
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Figure 4.2: High-fat diet (HFD) increases food consumption and
exacerbates weight gain caused by OLZ

Mice were fed HFD or LFD and administered OLZ or vehicle by osmotic
minipumps for four weeks. Food consumption and weight gain over the course
of the four week study is shown in panels A and B. Gonadal fat pads were
removed at sacrifice and percentage of gonadal fat mass to total body mass was
determined (panel C). Body composition was measured by dual energy x-ray
absorptiometry; representative scans are depicted (panel D). Data are means
±S.E.M.(n=4-8). a, P<0.05 effect of HFD; b, P <0.05 effect of OLZ as determined
with two-way ANOVA and Holm-Šidák multiple comparison test.
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Figure 4.3: HFD aggravates OLZ-induced liver injury

Livers were stained with H&E to demonstrate general hepatocellular
morphology (panel A, top). CAE staining was used to distinguish neutrophils from
other cell types (panel A, bottom). Neutrophils were counted (panel D) as
described in Chapter II. Transaminase levels were measured in plasma taken at
sacrifice (panels B and C). Liver weight is expressed as a percentage of total
body weight (panel E). Data are means ±S.E.M.(n=4-8). a, P<0.05 effect of
HFD; b, P <0.05 effect of OLZ as determined with two-way ANOVA and HolmŠidák multiple comparison test.
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Figure 4.4: OLZ and HFD promote hepatic lipid storage

Frozen sections of liver were stained with Oil Red O as described in
Materials and Methods (panel A, representative pictures) and staining was
quantitated in all samples (panel B). Lipids (TG and NEFA) were extracted from
pulverized liver samples and determined by colorimetric assay (panel C). Data
are means ±S.E.M.(n=4-8). a, P<0.05 effect of HFD; b, P <0.05 effect of OLZ as
determined with two-way ANOVA and Holm-Šidák multiple comparison test.
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Figure 4.5: Effects of OLZ and HFD on glucose and glycogen metabolism

OGTT was performed after 25 days of HFD or LFD feeding and exposure
to OLZ or vehicle (panel A). Glycogen was isolated from snap-frozen liver
samples and concentrations were determined by colorimetric assay (panel B).
Liver samples fixed at sacrifice were stained with Periodic acid-Schiff reagent to
identify glycogen (panel C). Data are means ±S.E.M.(n=4-8). a, P<0.05 effect of
HFD; b, P <0.05 effect of OLZ as determined with two-way ANOVA and HolmŠidák multiple comparison test.
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Figure 4.6: Effects of OLZ on apoptosis and lipid peroxidation

Frozen liver sections were stained using a modified TUNEL assay (panel
A, top row). Cells were counted (panel B) as described in the Histology section
of Chapter II, Experimental Procedures. Formalin-fixed liver sections were used
for immunohistochemical detection of 4-HNE adducts (panel A, bottom row).
Extent of staining (panel C) was quantitated as described in Experimental
Procedures. Data are means ±S.E.M.(n=4-8). a, P<0.05 effect of HFD; b, P
<0.05 effect of OLZ as determined with two-way ANOVA and Holm-Šidák
multiple comparison test.

70

71

CHAPTER V
PROTECTION FROM OLANZAPINE-INDUCED LIVER INJURY THROUGH
ACTIVATION OF THE NRF2 PATHWAY

A.

Introduction
Sulforaphane (SFN), an isothiocyanate phytochemical, is known to confer

antioxidant protection in vivo. Rather than directly reacting with oxidants,
however, SFN works by inducing Nrf2, a transcription factor that binds to the
promoter regions of several known antioxidant genes and enhances
detoxification (diagram, Figure 5.1). The route from SFN to Nrf2 is not entirely
established. In some studies, SFN’s isothiocyanate functional group is shown to
participate as a Michael acceptor in the nucleophilic reaction with cysteine
residues on Keap1.129 If Nrf2 remains bound to Keap1, it remains by definition in
the cytosol, where it does not influence gene transcription and will eventually be
targeted for degradation by the ubiquitin ligase Cul3.130 In addition to releasing
Nrf2 from Keap1, SFN may raise overall expression of Nrf2. Previous
experiments from this laboratory have shown that SFN increases Nrf2
abundance in both nuclear and cytoplasmic subcellular compartments, which
may account for the enhanced antioxidant protection observed by others.
Both obesity and OLZ-induced dysmetabolism are mediated in part by
oxidative stress. This implies that either condition may benefit from antioxidant
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intervention, e.g., SFN treatment. It may then be possible to prevent hepatic
injury from concurrent obesity and OLZ administration by pretreatment with SFN.
The purpose of the current study was to test the protective effect of SFN against
HFD- and OLZ-induced hepatic injury.
B.

Experimental procedures
1. Animals and treatments
Mice were administered HFD and OLZ for four weeks. Some mice were

also administered SFN as described in Chapter II.
2. Biochemical analyses and histology
ALT and AST were measured as previously described. H&E, TUNEL, and
4-HNE staining were performed as described in Chapter II.
3. Glycogen determinations
Glycogen was determined in aliquots of frozen liver as described in
Chapter II.
4. Lipid determinations
Lipids were extracted and analyzed as discussed in Chapter II.
C.

Results
1. SFN prevents steatosis and liver injury caused by co-administration
of HFD and OLZ
Histological changes were assessed by H&E staining (Figure 5.2, panel

A). HFD and OLZ, as expected, caused hepatic steatosis and mild inflammation.
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SFN treatment decreased fat accumulation in liver (panel A) in addition to
decreasing neutrophil infiltration/inflammation (panel A, inset). ALT and AST,
commonly used as markers of liver injury, decreased in parallel with the changes
in histology (panel B).
2. SFN improves lipid and carbohydrate metabolism in mice
administered HFD and OLZ
SFN blunted the characteristic triglyceride (TG) accumulation caused by
HFD and OLZ (Figure 5.2, panel B). SFN also rescued non-esterified fatty acid
(NEFA) levels which are paradoxically low during OLZ administration,70,104 and
increased hepatic glycogen storage, which is synergistically impaired by HFD
and OLZ (Figure 5.2, panel B and Figure 5.3, panel A).
3. SFN does not affect apoptosis with HFD and OLZ, but greatly
decreases lipid peroxidation
Adducts of 4-HNE, which amassed in large quantity after HFD and OLZ
exposure (see Chapter IV, Figure 4.4, panel A), appeared to nearly absent from
the tissue sections of SFN-treated mice (Figure 5.3, panel B) .The visually
apparent attenuation in staining was quantitated and determined to be a >20-fold
decrease in 4-HNE binding. Apoptosis (as determined by TUNEL staining) was
unaffected by SFN (Figure 5.3, panel C).
D.

Discussion
Obesity and antipsychotic-induced dysmetabolism may both be mediated

by oxidative stress (see Chapter I for general concepts of oxidative stress).
74

Whereas in obesity it is the reactive metabolites of sugars and lipids that may
cause oxidative stress,131,132 atypical antipsychotics may reduce expression of
antioxidant-encoding genes133 in addition to generating reactive metabolites.134
Antipsychotics can also be considered secondary contributors to oxidative stress
in that they promote obesity. Although the exact presentation of oxidative stress
in OLZ metabolism is not certain, it may be possible to prevent or treat the
weight-related side effects of OLZ using antioxidants.
In vitro, direct-acting antioxidants such as resveratrol consistently display
the ability to neutralize reactive oxygen species (ROS) and reactive drug
metabolites.135 In vivo, however, the success of antioxidant interventions has
been difficult to replicate.68 The pharmacokinetic and pharmacodynamic
limitations of direct-acting antioxidants like resveratrol may explain the
incongruous in vitro and in vivo experimental outcomes. Direct antioxidants are
reactive species themselves, making it difficult to ensure that, in the intact
organism, direct antioxidants reach the desired site of action before reacting with
other biological molecules. Agents like resveratrol and vitamin C are also prone
to redox cycling, meaning that they will readily act as both a reductant and an
oxidant in a complex living system.69 This means that in practice, high doses of
direct antioxidants can contribute to the same problems that they are intended to
solve.
Indirect antioxidants do not usually participate in redox reactions and
therefore offer an alternative approach to manage oxidative stress. SFN is
repeatedly shown to enhance Nrf2 accumulation, rather than interact directly with
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ROS.69 Here also, the indirect antioxidant sulforaphane was used successfully to
prevent oxidative stress in a model of chronic high-fat diet and olanzapine
administration. No exacerbation of oxidative stress was noted. The action of
intrinsic cellular defense mechanisms by SFN therefore exemplifies an effective
strategy to offset the side effects of antipsychotic treatment. It should be
considered as a therapeutic adjunct in future studies of patients prescribed OLZ.
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Figure 5.1: Simplified model of Nrf2 induction by SFN

SFN’s electrophilic side chain alkylates cysteine residues on Keap1. The
conformational change induced in Keap1 allows the release of its binding
partner, Nrf2. Unbound Nrf2 translocates to the nucleus and binds to antioxidant
response elements in DNA. See Discussion in section A of Chapter VI for
additional explanation of this mechanism.
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Figure 5.2: Influence of SFN on the metabolic outcomes of HFD and OLZ
co-administration

Panel A: H&E staining is shown at 100x and 400x (inset). Panel B: Weight
and other parameters were measured after HFD and OLZ treatment in the
presence or absence of SFN. Values for the SFN treatment group are expressed
as fold change vs. HFD and OLZ in the absence of SFN.
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Figure 5.3: Histological indices of protection from HFD and OLZ by SFN

Livers sections from animals given HFD and OLZ were compared with
liver sections from animals who were additionally co-administered SFN. Staining
for glycogen (panel A), lipid peroxidation (panel B), and apoptosis (panel C) was
performed as described in Experimental Procedures, Chapter II.
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CHAPTER VI
DISCUSSION AND CONCLUSIONS

A.

Biochemical pathways involved in NAFLD and/or OLZ toxicity and

potential pharmacological interventions
1. AMPK
One of the major regulators of energy homeostasis in mammalian cells is
the 5' adenosine monophosphate-activated protein kinase (AMPK).113 The ratio
of AMP:ATP is roughly proportional to cellular nutrient availability;136 therefore,
AMPK’s ability to respond to changes in the AMP:ATP ratio makes it an
important coordinator of various metabolic functions. When AMPK’s α subunit is
phosphorylated at threonine-172, the kinase is activated and promotes ATPgenerating catabolic processes, e.g., fatty acid oxidation. It is through increased
catabolism, in fact, that the AMPK-activating drug metformin is thought to reverse
fatty liver and glucose intolerance.137
Along with its well-established roles in energy homeostasis, research has
also demonstrated a link between AMPK activation and atypical antipsychotics
such as OLZ. AMPK activation in the hypothalamus is frequently reported after
OLZ administration, leading many researchers to consider its mechanistic
relevance to treatment-emergent obesity.138,139 AMPK activation has also been
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shown in PC12 cells (i.e., non-neuronal cells) after OLZ exposure, demonstrating
that AMPK activation with OLZ is not restricted to the CNS.140 Meltzer141 and
others have suggested that AMPK activation may be inducing the metabolic side
effects of OLZ. It remains unclear, though, why AMPK activation by OLZ would
promote symptoms of the metabolic syndrome when AMPK activation by
metformin has clear antidiabetic effects.142 The moderate success of metformin
in treating OLZ-induced diabetes has only further confounded the search for
answers.143
2. mTOR
The mammalian target of rapamycin (mTOR) is a widely-expressed
serine-threonine kinase (see Tsang109 for review). It is found as part of two
functional complexes, mTORC1 and mTORC2, both of which are major
mediators of cell growth and survival. mTOR may be seen as a counterpart to
AMPK: while AMPK is activated under conditions of nutrient depletion, mTOR is
typically activated during times of adequate or surplus nutrient availability.144 The
functions of mTOR, then, are mostly anabolic, including RNA transcription145 and
adipogenesis.146 While some degree of mTOR activation is necessary,
excessive activation of mTOR is implicated in obesity and diabetes. Constitutive
mTOR activation in vitro has been shown to impair insulin signaling.147 In further
support of mTOR’s hypothesized role in metabolic disorders, a clinical study
published just earlier this year reported that mTORC1 signaling is activated in
placental samples taken from obese mothers.148
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There is no clear link between mTOR and atypical antipsychotic drug
actions; however, they are connected by a wealth of circumstantial evidence.
Among its numerous other functions the mTOR pathway regulates memory and
synaptic plasticity.149 Deletion of Rictor, the mTORC2 binding partner, in a
mouse model induces schizophrenia-like behaviors and abnormal
neurotransmission.150 Rapamycin, the most extensively studied mTOR inhibitor,
has been suggested as a potential treatment for mood disorders;151 at the same
time, ketamine, a known mTOR inducer, demonstrably improved bipolar disorder
in a handful of small clinical trials.152,153 There are still huge gaps in our
knowledge of mTOR and neurological dysfunction. At present, there are no
FDA-approved treatments for mental illness or obesity that directly target mTOR.
3. Nrf2
NF-E2-related factor 2 (Nrf2) is a basic leucine zipper transcription factor
universally expressed in the cytosol of eukaryotic cells.154,155 In the presence of
electrophiles or reactive oxygen species, Nrf2 is released from its repressor
protein Keap1 and the ubiquitin ligase Cul3.156,157 Upon its release from Keap1
and Cul3, Nrf2 moves to the nucleus, where it can then bind to response
elements in DNA158 and influence antioxidant gene transcription. Because
reactive oxygen species are proposed culprits in many disease states,53-56 Nrf2inducing chemicals are being explored as therapeutic agents.69 Nrf2’s ability to
upregulate expression of cytoprotective genes makes it a potentially important
target for drug development.
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Nrf2 and mTOR are not usually considered as parts of a common
pathway. However, these pathways do intersect, most notably at the level of
insulin signaling.159 The actions of rapamycin and the experimental Nrf2 inducer
CDDO-Im also suggest cross-talk between the pathways: Nrf2-mutated lung
cancer cells are responsive to rapamycin,160 while CDDO-Im inhibits insulinmediated mTOR phosphorylation.161
B.

Major findings of this dissertation
It has been stated several times throughout this work that OLZ is an

effective drug for treating psychiatric illnesses including schizophrenia and
bipolar disorder.162,163 The benefits of OLZ are countermanded by side effects
such as weight gain, glucose intolerance and dyslipidemia which impact not only
psychiatric treatment compliance but also increase the health risks to patients.
An improved understanding of OLZ actions in the peripheral tissues may
therefore identify new approaches to increase the long-term safety and utility of
this drug. Experiments in Chapter III were performed to reveal and characterize
the mechanism(s) of OLZ-induced toxicity. In Chapter IV, the experiments of the
previous chapter were expanded to ascertain possible interactions of OLZ and
the typical Western diet. The experiments in Chapter V tested SFN as an
adjunct to OLZ administration. Specific findings from each of these chapters are
discussed in the next paragraphs.
1. OLZ simultaneously activates AMPK and mTOR
As has been observed previously, OLZ administration increased body
weight and adiposity in mice (Figure 3.2) in the absence of a high-fat diet or a
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detectable increase in food consumption. These data suggest that OLZ
administration may directly alter energy usage in vivo. Previous experiments
from other laboratories have shown that OLZ administration dysregulates
carbohydrate and lipid metabolism (see Coccurrello94 for review). Indeed, here,
OLZ administration caused a complex phenotypic alteration in hepatic
carbohydrate metabolism. OLZ administration increased glycolysis without an
apparent increase in mitochondrial respiration (Figures 3.4 and 3.6) and favored
glycogen depletion (Figures 3.4 and 3.7). OLZ administration also caused a
slight but significant glucose intolerance (Figure 3.7) and increased postprandial
plasma glucose (Table 3.1). A shift to an elevated, but incomplete (i.e.,
anaerobic), glycolysis would favor ATP generation from alternate sources, such
as lipid oxidation. In support of the hypothesized shift to glycolysis, OLZ
administration increases plasma lactic acid levels in humans.94 Furthermore,
Albaugh et al.104 demonstrated that OLZ administration lowers the respiratory
exchange ratio (RER) in rats, indicative of a preferential shift to NEFA over
carbohydrates as fuel. These results are in line with the observation here that
hepatic and plasma triglycerides were elevated by OLZ administration (Figure 3.3
and Table 3.1), without a commensurate increase in hepatic NEFA (Figure 3.3).
Within the cell, carbohydrate and lipid metabolism are usually under the
tight control of the protein kinases AMPK and mTOR. Both AMPK and mTOR
are known to act as “sensors” of cellular energy status and help to maintain
homeostasis.113,164 In general, the downstream effects of AMPK activation are
considered catabolic and favor ATP generation during energy depletion.
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Glycolysis, for example, is enhanced by AMPK. Signaling downstream of AMPK
also inhibits ATP-consuming processes.165 In contrast to AMPK, mTOR is
activated during times of high nutrient availability and favors storage of excess
nutrients (e.g., as triglycerides). Activation of the mTOR pathway promotes ATPconsuming processes such as protein and lipid synthesis through its downstream
targets p70S6K and 4EBP1. Earlier studies have demonstrated that AMPK is
activated in the CNS by OLZ administration.140 Furthermore, OLZ increases
p70S6K and 4EBP1 phosphorylation in cultured hepatocytes, indicative of mTOR
activation.166 The experiments here demonstrate, for the first time, that OLZ in
vivo concomitantly activates AMPK and mTOR pathways in the liver. AMPK and
mTOR are generally differentially activated and mediate opposing cellular
functions. 144 The outcomes of OLZ administration on hepatic metabolism reflect,
in part, these contradictory inputs. These data suggest that treatment with OLZ
results in a pseudo-fasted state wherein metabolic resources are abundant, but
cannot be efficiently used. The reason for OLZ’s concurrent activation of AMPK
and mTOR is not immediately clear. Should OLZ indeed induce a pseudo-fasted
state, the activation of AMPK may be, in principle, via the classical accumulation
of AMP.
2. OLZ modulates intracellular amino acid transport, which may affect
energy homeostasis
OLZ is reported elsewhere to modulate glutamine, glutamate and BCAA
concentrations in brain and periphery, as well as key genes in glutamate
metabolism.42,101,108,167-169 The functional therapeutic importance of these amino
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acid changes is uncertain, but may be related to maintenance of the so-called
“glutamate-glutamine cycle.”170-172 This is a model which proposes that
excitatory neurotransmission is carefully maintained through the coordinated
transport of glutamate and glutamine. The cycle is neither closed nor
stoichiometric173 but nonetheless finely synchronizes amino acid concentrations
between neuronal and non-neuronal compartments. In the experiments
presented here, OLZ administration modulated glutamate, glutamine, and leucine
flux, while pathway analysis pointed to increases in the amino acid transporters
LAT1, SNAT2, and EAAT3, among others. The actions of OLZ seen here and in
others’ work are consistent with the glutamatergic model of mental illness, which
proposes that psychotic disorders are (at least partly) disorders of excitatory
amino acid metabolism.123 Notably, hepatic mTOR activation is also mediated by
these same fluctuations in amino acid metabolism.97,106,116,174-176 Meta-analyses
have demonstrated that targeting AMPK with metformin confers a significant,
albeit small, protective effect against some of the metabolic effects of OLZ.115
However, targeting mTOR overactivation may be a more successful approach.
3. HFD aggravates liver injury caused by OLZ
Another important aspect of this work is that the combination of HFD and
OLZ administration significantly increased indices of liver injury (Figure 4.3) in
mice. Elevation of liver enzymes is described as a common reaction with OLZ
administration, resulting in drug discontinuation.177 The pathologic changes in
liver due to OLZ alone (Table 3.1 and Figure 4.3) are analogous to those caused
by HFD. However, in many of the experiments performed here, injury from HFD
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and OLZ together was greater than the injury resulting from either factor on its
own, possibly indicating that these factors mediate toxicity through separate,
distinct mechanisms. NAFLD is a spectrum of liver diseases, ranging from the
relatively benign simple steatosis to hepatocellular carcinoma.27 Although the
prevalence of simple steatosis in individuals at risk for NAFLD can be very high,46
the prevalence of NASH is much lower in this population (~40%).46 These
factors emphasize that the risk for developing more severe stages of NAFLD
(i.e., NASH and beyond) is not based solely on obesity, but is rather mitigated by
other factors.47,48 It is likely that OLZ treatment could be such a factor that
enhances the progression of NAFLD.
4. SFN counteracts oxidative stress caused by HFD and OLZ
Much of the research regarding Nrf2 has focused on the pathway’s
function in mitigating oxidative stress.178 Though antioxidant defense is a
primary feature of Nrf2 pathway induction, recent investigation shows that Nrf2
also exerts regulatory effects on lipid metabolism.179 180 Moreover, because
oxidative stress and altered lipid metabolism are both correlated with the side
effects of OLZ, Nrf2 induction (using SFN) was tested as a method of minimizing
these side effects.
SFN, as predicted, offset many of the side effects of OLZ without causing
apparent injury to the mice (Figure 5.2). The most significant improvements seen
were in weight, adiposity, and lipid peroxidation. The favorable results with SFN
suggest that Nrf2 induction may be used to decrease the incidence of additional
medical complaints that can be caused by OLZ. Consequently, SFN
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administration might also encourage patient adherence with psychiatric treatment
regimens.
C.

Strengths and weaknesses of this dissertation
1. Strengths
There are many strengths of this dissertation. One such strength is that it

identifies a new mechanism in the development of metabolic dysregulation
caused by OLZ. It also offers additional evidence for the worsening of liver
disease during antipsychotic administration and suggests a possible strategy for
prevention. The research presented in this text thus advances the ongoing
search for better-tolerated pharmacological treatments for mental illness.
Another strength of this dissertation is the use of whole animal models.
Most of the experiments described here were performed in vivo, except where to
do so would be impractical or impossible (e.g., measuring oxygen consumption in
real time with multiple doses of OLZ). Obesity and mental illness are both
complex phenomena, not limited to one particular organ or cell type. Also, like
most psychiatric medications, OLZ is widely systemically distributed, as this is
the most practical method of delivering the drug to the CNS.181 As such it is
preferable to study the effects of OLZ in a complex, dynamic system such as an
intact organism.
2. Weaknesses
The use of animal models, while a strength, is also a potential weakness.
Although in vivo research is preferred for many pharmacological and metabolic
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studies, no animal model can completely recapitulate the human condition. Apart
from obvious differences in sleeping, eating, and social interactions, there is also
no rodent model that exactly represents human mental illness182 or non-alcoholic
liver disease progression from steatosis to NASH.61
Another weakness of this study is that all conditions are not adequately
represented in the SFN experiment. The combination of OLZ and low-fat/control
diet was not tested with SFN, nor was SFN administered in any diet group in the
absence of OLZ. Additionally, increased drug efflux is a known consequence of
Nrf2 induction.183 More research will be needed to determine whether or not
SFN is promoting OLZ removal and perhaps jeopardizing the therapeutic
potential of OLZ.
D.

Future directions
Research answers scientific questions, but just as often it creates new

questions. The following are future experiments that logically proceed from the
findings of this dissertation:
1. What are the effects of combined HFD and OLZ exposure on AMPK
and mTOR expression?
Because the experiments described in Chapters IV and V were largely
concerned with pathology and not biochemical mechanism of development,
mTOR, AMPK, and related proteins in these signaling pathways were not
measured in animals treated with HFD and/or SFN. Obesity and high-fat diet by
themselves reproducibly activate mTOR signaling;184 however, the effects of
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concomitant HFD and OLZ on mTOR regulation have not been explored.
Likewise, the existence of a relationship between mTOR and Nrf2 is not firmly
established; it would therefore be interesting to determine how mTOR signaling
and expression are mediated with SFN alone, SFN in combination with HFD, and
SFN with concurrent HFD and OLZ.
2. Does SFN influence absorption, distribution, metabolism, or
excretion of OLZ?
In the Weaknesses section of this chapter, it was mentioned that
metabolic response to SFN was not observed in all possible conditions, i.e., with
low-fat control diet or without OLZ. While it is clear that SFN prevented weight
gain and liver injury in the HFD + chronic OLZ model, it is not certain how SFN
did this. SFN is widely shown to prevent oxidative stress and is also understood
to mediate lipid metabolism, but neither function of SFN was conclusively
determined in any of the preceding experiments. Perhaps even more
importantly, it was not determined how SFN co-administration affects OLZ
disposition. For example, glucuronidation is recognized to be increased by SFN
administration,185 which may suggest that SFN worked in this model simply by
increasing OLZ excretion and removal. As Bever and Perry1 noted in their
review, OLZ is metabolized by many known mechanisms, so it is unlikely that a
change in any one pathway would affect total clearance of OLZ. Still, excessive
clearance of OLZ should be ruled out in future experiments.
3. How does OLZ behave in other peripheral locations, such as adipose
tissue?
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The approved uses of OLZ are psychiatric disorders. The most common
off-label uses for OLZ are mental illness-related as well. Naturally, much of the
existing literature is devoted to the study of OLZ in central nervous system tissue.
In order to gain a more complete understanding of how OLZ works, its effects
should be more extensively studied in non-neuronal regions, both in the intact
organism and in cell culture. A prime candidate for future study is adipose tissue
which, despite its known role as an arbiter of leptin secretion and CNS
recognition of satiety,186 remains poorly investigated. Skeletal muscle is also
overlooked in antipsychotic research, even though myopathy is sometimes
reported during OLZ administration to human patients,187 and should also be
thoroughly investigated.
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ABBREVIATIONS

4EBP1

eukaryotic translation initiation factor 4E binding protein 1

Acly

ATP citrate lyase

Akt

protein kinase B

ALT

alanine aminotransferase

AMPK

AMP-activated protein kinase

AST

aspartate aminotransferase

CNS

central nervous system

Cpt1a

carnitine palmitoyltransferase 1a

DEXA

dual-energy x-ray absorptiometry

Fasn

fatty acid synthase

FCCP

carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone

Gck

glucokinase

Glut1

glucose transporter type 1

Glut4

glucose transporter type 4

Gsk3b

glycogen synthase kinase-3β
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H&E

hematoxylin and eosin

HDL

high-density lipoprotein

HFD

high-fat diet; TD.88137 Adjusted Calories diet

LAT1

L-type amino acid transporter 1

LDL

low-density lipoprotein

LFD

low-fat diet; TD.08485 Low-Fat Control Diet

MTBSTFA

N-(tert-butyldimethylsilyl)-N-methyltrifluoroacetamide

mTOR

mammalian target of rapamycin

NAFLD

non-alcoholic fatty liver disease

NASH

non-alcoholic steatohepatitis

NEFA

non-esterified fatty acids

OCR

oxygen consumption rate

OGTT

oral glucose tolerance test

OLZ

olanzapine

p70S6K

70 kDa ribosomal protein s6 kinase

Pck1

phosphoenolpyruvate carboxykinase 1

PAS

periodic acid-Schiff reagent

PPR

proton production rate

SLC7A5

solute carrier family 7 member 5
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SLC38A2

solute carrier family 38 member 2

SNAT2

system A amino acid transporter 2

Srebf1

sterol regulatory element binding protein 1

TBDMSCI

tert-butyldimethylchlorosilane

TG

triglycerides

VLDL

very low-density lipoprotein
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